LOGIN  |  REGISTER
Amneal Pharmaceuticals

PreOmics Introduces New ENRICH-iST Kits and Novel Workflow for Unbiased, Affordable Plasma and Serum Proteomics by LC-MS

June 05, 2023 | Last Trade: US$56.00 1.73 -3.00
  • ENRICH-iST enables unbiased enrichment of lower abundant plasma and serum proteins by 50% to more than 100% in human and rodent plasma proteomics in a cost-effective, fast 5-hour workflow
  • ENRICH-iST utilizes non-functionalized paramagnetic microbeads supporting automated platforms
  • ENRICH-iST enables protein enrichment and tryptic digestion on only 20 microL of starting material

HOUSTON / Jun 05, 2023 / Business Wire / At ASMS 2023, PreOmics GmbH announces the launch of its new ENRICH-iST™ kits, which enable biologically unbiased enrichment of lower abundant plasma and serum proteins onto non-functionalized paramagnetic particles, enhancing typical depths of plasma proteomics analysis by 50% to more than 100%, compared to neat plasma or serum proteomics without depletion or enrichment. The novel ENRICH-iST workflow enables fast and robust processing of up to 96 plasma samples in parallel for reproducible large-cohort translational and clinical research and validation. The affordable ENRICH-iST routine enrichment workflow nicely complements existing ultra-deep plasma proteomics discovery research workflows that either use automated bead depletion or nanoparticle array enrichment.

The ENRICH-iST technology offers a simple, fast (<5h total) and cost-effective solution for proteomic sample processing of plasma or serum from various species, including human, rodents, NHPs, dogs and pigs. Requiring only 20 microL of starting material, it consistently delivers reproducible, enhanced results for LC-MS analysis, e.g., by DIA-PASEF timsTOF 4D Proteomics mass spectrometry. Utilizing non-functionalized paramagnetic microbeads, the technology enables biologically unbiased enrichment of lower abundant proteins, and supports liquid handling automation platforms, such as Tecan FLUENT systems.

Dr. Andreas-David Brunner, Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, states: “We routinely work with biofluid cohorts collected from preclinical species. The novel ENRICH technology from PreOmics allowed us to achieve reliable and in-depth proteomic data without laborious method development. The new kit worked out of the box; the workflow is intuitive and can be completely automated. This solution allows us to standardize our processes completely, and significantly improves our throughput.”

In a benchmark study, plasma and serum samples from human, mouse and rat specimens (from suppliers Sigma Aldrich, BioIVT and Diaserve Laboratories GmbH) were processed using the novel ENRICH-iST workflow in comparison to antibody-based depletion, as well as to unprocessed neat samples. Peptides were analyzed on a timsTOF HT mass spectrometer (Bruker Daltonics) in DIA-PASEF mode using a 30-minute nanoLC gradient. The ENRICH-iST workflow was shown to increase the proteomic depth of peptides and proteins 1.5x – 2.2x -fold in comparison to neat samples. Typical Coefficients of Variation (CV) within replicates were below 12%, emphasizing high repeatability of the ENRICH-iST workflow. Matching the identified proteins with the plasma proteome database revealed a superior coverage for the ENRICH-iST workflow over neat and depleted samples with identified proteins covering a larger dynamic range. ENRICH-iST showed higher precision over the measured abundance range in comparison to the depletion workflow.

Dr. Catherine Nury, Manager Proteomics, Philip Morris International, Switzerland, comments: “We tested several options for biomarker discovery on plasma samples, but many were long and tedious. With the novel ENRICH technology, we have a fast, efficient, and reliable enrichment workflow to get deeper into the proteome from human plasma and serum. We use the ENRICH-iST 96x kits and are delighted by the reproducibility and ease of the kit. We really enjoyed working with the PreOmics team, who are always there to support us. We would strongly recommend the kit to other plasma and serum proteomics users.”

Automation is key for high-throughput plasma proteomics and Luca Valeggia, Senior Vice President - Lab Automation, at Tecan, adds: “We are delighted to continue our collaboration with PreOmics. By automating their new ERICH-iST kit on our Fluent workstation, we’re enabling robust and reproducible high-throughput sample preparation for large cohort studies, helping to further accelerate progress in this rapidly advancing field.”

Have a look yourself: PreOmics representatives will be at ASMS booth #827 to showcase the ENRICH-iST application note. Additional information can be accessed at www.preomics.com/products/enrich-ist.

About PreOmics GmbH

PreOmics empowers our clients in life sciences to establish biological knowledge through efficient, reliable solutions and workflows that set the standard for protein analysis. Our team spirit, energy, and commitment empower us to be both creative and quality focused – a trusted partner with deeply rooted scientific experience. We envisage a future with revolutionary proteomic discovery processes open for everyone. Tools that reveal hidden causes of diseases, ensure sustainable nutrition, and provide diagnoses that enhance lives and society.

Website: www.preomics.com
Address: Am Klopferspitz 19 | 82152 Planegg/Martinsried | Germany

photo

photo

Viking Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB